Ticker archive · $MBRX

$MBRX Filing Signals & Market Reactions

Delayed, SEO-crawlable recaps of AI-scored catalysts for $MBRX — including observed post-filing price moves. Live streaming stays exclusive to VIP.

? All delayed signals

$MBRX

$MBRX – Moleculin Completes Dosing in Part A of Pivotal AML Trial; Readout in Q1 2027

Moleculin Biotech, Inc.

2026-10-30 00:00:00 UTC · SEC_8K · All $MBRX

?? Positive AI Sentiment (+2.5 / 10)

Fully dosed randomized, double-blind n=90 Part A cohort evaluating Annamycin with cytarabine for R/R AML.
Management confirms data readout remains on track for Q1 2027 to select Part B dose.
Blinded interim reviews show continued absence of cardiotoxicity.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?